Statin Use and Musculoskeletal Pain Among Adults With and Without Arthritis



      Musculoskeletal symptoms are common adverse effects of statins, yet little is known about the prevalence of musculoskeletal pain and statin use in the general population.


      We conducted a cross-sectional study of the National Health and Nutrition Examination Survey 1999-2004. We estimated the prevalence of self-reported musculoskeletal pain according to statin use and calculated prevalence ratio estimates of musculoskeletal pain obtained from adjusted multiple logistic regression modeling.


      Among 5170 participants without arthritis, the unadjusted prevalence of musculoskeletal pain was significantly higher for statin users reporting pain in any region (23% among statin users, 95% confidence interval [CI], 19-27, compared with 18% among those not using statins, 95% CI, 17-20; P=.02) and in the lower extremities (12% among statin users, 95% CI, 8-16, compared with 8% among those not using statins, 95% CI, 7-9; P=.02). Conversely, among 3058 participants with arthritis, statin use was not associated with higher musculoskeletal pain in any region. After controlling for confounders, among those without arthritis, statin use was associated with a significantly higher prevalence of musculoskeletal pain in any region, the lower back, and the lower extremities (adjusted prevalence ratios: 1.33 [CI, 1.06-1.67]; 1.47 [CI, 1.02-2.13]; 1.59 [CI, 1.12-2.22], respectively). Among participants with arthritis, no association was observed between musculoskeletal pain and statin use on adjusted analyses.


      In this population-based study, statin use was associated with a higher prevalence of musculoskeletal pain, particularly in the lower extremities, among individuals without arthritis. Evidence that statin use was associated with musculoskeletal pain among those with arthritis was lacking.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cannon C.P.
        • Steinberg B.A.
        • Murphy S.A.
        • Mega J.L.
        • Braunwald E.
        Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.
        J Am Coll Cardiol. 2006; 48: 438
        • Cheung B.M.Y.
        • Lauder I.J.
        • Lau C.P.
        • Kumana C.R.
        Meta analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes.
        Br J Clin Pharmacol. 2004; 57: 640-651
        • Fonarow G.C.
        • Watson K.E.
        Effective strategies for long-term statin use.
        Am J Cardiol. 2003; 92: 27-34
        • Maggon K.
        Best-selling human medicines 2002-2004.
        Drug Discov Today. 2005; 10: 739-742
        • Mann D.
        • Reynolds K.
        • Smith D.
        • Muntner P.
        Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program Guidelines (September).
        Ann Pharmacother. 2008; 42 (Epub 2008 Jul 22): 1208-1215
        • McKenney J.M.
        • Davidson M.H.
        • Jacobson T.A.
        • Guyton J.R.
        Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.
        Am J Cardiol. 2006; 97: 89C-94C
        • Thompson P.D.
        • Clarkson P.
        • Karas R.H.
        Statin-associated myopathy.
        JAMA. 2003; 289: 1681-1690
        • Buettner C.
        • Davis R.B.
        • Leveille S.G.
        • Mittleman M.A.
        • Mukamal K.J.
        Prevalence of musculoskeletal pain and statin use.
        J Gen Intern Med. 2008; 23: 1182-1186
      1. National Health and Nutrition Examination Survey.
        (Accessed February 2, 2011)
      2. National Health and Nutrition Examination Survey, NCHS Research Ethics Review Board (ERB) Approval.
        (Accessed February 2, 2011)
        • Bieler G.S.
        • Brown G.G.
        • Williams R.L.
        • Brogan D.J.
        Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data.
        Am J Epidemiol. 2010; 171: 618-623
        • Bruckert E.
        • Hayem G.
        • Dejager S.
        • Yau C.
        • Begaud B.
        Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients the PRIMO study.
        Cardiovasc Drugs Ther. 2005; 19: 403-414
        • Franc S.
        • Dejager S.
        • Bruckert E.
        • Chauvenet M.
        • Giral P.
        • Turpin G.
        A comprehensive description of muscle symptoms associated with lipid-lowering drugs.
        Cardiovasc Drugs Ther. 2003; 17: 459-465
        • Hansen K.E.
        • Hildebrand J.P.
        • Ferguson E.E.
        • Stein J.H.
        Outcomes in 45 patients with statin-associated myopathy.
        Arch Intern Med. 2005; 165: 2671-2676
        • Frieze D.A.
        Musculoskeletal pain associated with corticosteroid therapy in cancer.
        Curr Pain Headache Rep. 2010; 14: 256-260
        • Kuncl R.W.
        • Duncan G.
        • Watson D.
        • Alderson K.
        • Rogawski M.A.
        • Peper M.
        Colchicine myopathy and neuropathy.
        N Engl J Med. 1987; 316: 1562-1568
        • Kashani A.
        • Phillips C.O.
        • Foody J.M.
        • et al.
        Risks associated with statin therapy: a systematic overview of randomized clinical trials.
        Circulation. 2006; 114: 2788-2797
        • Silva M.
        • Matthews M.L.
        • Jarvis C.
        • et al.
        Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
        Clin Ther. 2007; 29: 253-260
        • Silva M.A.
        • Swanson A.C.
        • Gandhi P.J.
        • Tataronis G.R.
        Statin-related adverse events: a meta-analysis.
        Clin Ther. 2006; 28: 26-35
        • Ladouceur M.
        • Rahme E.
        • Pineau C.A.
        • Joseph L.
        Robustness of prevalence estimates derived from misclassified data from administrative databases.
        Biometrics. 2007; 63: 272-279
        • Losina E.
        • Barrett J.
        • Baron J.A.
        • Katz J.N.
        Accuracy of Medicare claims data for rheumatologic diagnoses in total hip replacement recipients.
        J Clin Epidemiol. 2003; 56: 515-519
        • Sacks J.J.
        • Harrold L.R.
        • Helmick C.G.
        • Gurwitz J.H.
        • Emani S.
        • Yood R.A.
        Validation of a surveillance case definition for arthritis.
        J Rheumatol. 2005; 32: 340-347
      3. FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury.
        (Accessed February 2, 2011)
      4. FDA Public Health Advisory for Crestor (rosuvastatin).
        (Accessed February 2, 2011)